Roles of Serum Calcium, Phosphorus, PTH and ALP on Mortality in Peritoneal Dialysis Patients: A Nationwide, Population-based Longitudinal Study Using TWRDS 2005-2012

被引:37
作者
Liu, Chung-Te [1 ,2 ,3 ]
Lin, Yen-Chung [2 ,3 ,4 ]
Lin, Yi-Chun [5 ,6 ]
Kao, Chih-Chin [2 ,3 ,4 ]
Chen, Hsi-Hsien [2 ,4 ]
Hsu, Chih-Cheng [7 ]
Wu, Mai-Szu [2 ,4 ]
机构
[1] Taipei Med Univ, Wanfang Hosp, Dept Internal Med, Div Nephrol, Taipei, Taiwan
[2] Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med, Taipei, Taiwan
[3] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan
[4] Taipei Med Univ Hosp, Dept Internal Med, Div Nephrol, Taipei, Taiwan
[5] Taipei Vet Gen Hosp, Dept Med, Div Endocrinol & Metab, Taipei, Taiwan
[6] Natl Yang Ming Univ, Fac Med, Taipei, Taiwan
[7] Natl Hlth Res Inst, Inst Populat Hlth Sci, Zhunan, Taiwan
关键词
INTACT PARATHYROID-HORMONE; STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; ALKALINE-PHOSPHATASE; MINERAL METABOLISM; BONE METABOLISM; KIDNEY-DISEASE; RISK; ASSOCIATION; SURVIVAL;
D O I
10.1038/s41598-017-00080-4
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Biomarkers of chronic kidney disease-mineral and bone disorder (CKD-MBD) correlate with morbidity and mortality in dialysis patients. However, the comparative roles of each CKD-MBD biomarker remained undetermined on long-term peritoneal dialysis (PD) patients. This retrospective study, employing a population-based database, aimed to evaluate the performance and provide the best evidence of each biomarker of CKD-MBD as predictor of all-cause mortality. Throughout the 8-year study period, total 12,116 PD patients were included in this study. Cox proportional regression and Kaplan-Meier method were used for survival analysis. For Cox regression model, baseline measurements and time-varying covariates were used for analysis. In Cox regression model using time-dependent covariates, serum calcium level of >= 9.5 mg/dL was associated with increased mortality. For phosphorus, serum levels of either >= 6.5 mg/dL or <3.5 mg/dL were associated with increased mortality. For parathyroid hormone (PTH), higher serum levels were not associated increased mortality. For alkaline phosphatase (ALP), mortality increased at levels >= 100 IU/L. Our findings suggested that the detrimental effect of ALP on survival was more consistent, while serum calcium, phosphorus and PTH may have a less prominent effect on mortality. This study provided additional information for manipulating CKD-MBD biomarkers in PD patients.
引用
收藏
页数:9
相关论文
共 42 条
[1]  
[Anonymous], 2012, Kidney Int Suppl (2011), V2, P299
[2]   Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation [J].
Avram, MM ;
Mittman, N ;
Myint, MM ;
Fein, P .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (06) :1351-1357
[3]   High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death [J].
Blayney, Margaret J. ;
Pisoni, Ronald L. ;
Bragg-Gresham, Jennifer L. ;
Bommer, Juergen ;
Piera, Luis ;
Saito, Akira ;
Akiba, Takashi ;
Keen, Marcia L. ;
Young, Eric W. ;
Port, Friedrich K. .
KIDNEY INTERNATIONAL, 2008, 74 (05) :655-663
[4]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[5]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[6]   Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: Implication for treatment decisions [J].
Cantor, Tom ;
Yang, Zan ;
Caraiani, Nicolae ;
Ilamathi, Ekambaram .
CLINICAL CHEMISTRY, 2006, 52 (09) :1771-1776
[7]   Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease [J].
de Oliveira, Rodrigo A. ;
Barreto, Fellype C. ;
Mendes, Monique ;
dos Reis, Luciene M. ;
Castro, Joao Henrique ;
Britto, Zita Maria L. ;
Marques, Igor D. B. ;
Carvalho, Aluizio B. ;
Moyses, Rosa M. ;
Jorgetti, Vanda .
KIDNEY INTERNATIONAL, 2015, 87 (05) :1039-1045
[8]  
Fein Paul A, 2013, Adv Perit Dial, V29, P61
[9]   Assessment of renal osteodystrophy in dialysis patients: Use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology [J].
Fletcher, S ;
Jones, RG ;
Rayner, HC ;
Harden, P ;
Hordon, LD ;
Aaron, JE ;
Oldroyd, B ;
Brownjohn, AM ;
Turney, JH ;
Smith, MA .
NEPHRON, 1997, 75 (04) :412-419
[10]   Study design and subject baseline characteristics in the ADVANCE study: effects of cinacalcet on vascular calcification in haemodialysis patients [J].
Floege, Juergen ;
Raggi, Paolo ;
Block, Geoffrey A. ;
Torres, Pablo Urena ;
Csiky, Botond ;
Naso, Agostino ;
Nossuli, Kaldin ;
Moustafa, Moustafa ;
Goodman, William G. ;
Lopez, Nicole ;
Downey, Gerry ;
Dehmel, Bastian ;
Chertow, Glenn M. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (06) :1916-1923